[18F]FDG-PET/CT in Idiopathic Inflammatory Myopathies: Retrospective Data from a Belgian Cohort
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Yildiz, H.; D’Abadie, P.; Gheysens, O. The Role of Quantitative and Semi-quantitative [(18)F]FDG-PET/CT Indices for Evaluating Disease Activity and Management of Patients With Dermatomyositis and Polymyositis. Front. Med. 2022, 9, 883727. [Google Scholar] [CrossRef] [PubMed]
- Bohan, A.; Peter, J.B. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 1975, 292, 403–407. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Betteridge, Z.; McHugh, N. Myositis-specific autoantibodies: An important tool to support diagnosis of myositis. J. Intern. Med. 2016, 280, 8–23. [Google Scholar] [CrossRef] [PubMed]
- Halilu, F.; Christopher-Stine, L. Myositis-specific Antibodies: Overview and Clinical Utilization. Rheumatol. Immunol. Res. 2022, 3, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Ashton, C.; Paramalingam, S.; Stevenson, B.; Brusch, A.; Needham, M. Idiopathic inflammatory myopathies: A review. Intern. Med. J. 2021, 51, 845–852. [Google Scholar] [CrossRef]
- Mammen, A.L.; Chung, T.; Christopher-Stine, L.; Rosen, P.; Rosen, A.; Doering, K.R.; Casciola-Rosen, L.A. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011, 63, 713–721. [Google Scholar] [CrossRef] [Green Version]
- Selva-O’Callaghan, A.; Pinal-Fernandez, I.; Trallero-Araguas, E.; Milisenda, J.C.; Grau-Junyent, J.M.; Mammen, A.L. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018, 17, 816–828. [Google Scholar] [CrossRef]
- Lundberg, I.E.; Tjarnlund, A.; Bottai, M.; Werth, V.P.; Pilkington, C.; de Visser, M.; Alfredsson, L.; Amato, A.A.; Barohn, R.J.; Liang, M.H.; et al. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 2017, 69, 2271–2282. [Google Scholar] [CrossRef]
- Paganoni, S.; Amato, A. Electrodiagnostic evaluation of myopathies. Phys. Med. Rehabil. Clin. N. Am. 2013, 24, 193–207. [Google Scholar] [CrossRef] [Green Version]
- Malartre, S.; Bachasson, D.; Mercy, G.; Sarkis, E.; Anquetil, C.; Benveniste, O.; Allenbach, Y. MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathol. 2021, 31, e12954. [Google Scholar] [CrossRef]
- Pinal-Fernandez, I.; Casal-Dominguez, M.; Carrino, J.A.; Lahouti, A.H.; Basharat, P.; Albayda, J.; Paik, J.J.; Ahlawat, S.; Danoff, S.K.; Lloyd, T.E.; et al. Thigh muscle MRI in immune-mediated necrotising myopathy: Extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann. Rheum. Dis. 2017, 76, 681–687. [Google Scholar] [CrossRef] [PubMed]
- Tasca, G.; Monforte, M.; De Fino, C.; Kley, R.A.; Ricci, E.; Mirabella, M. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve 2015, 52, 956–962. [Google Scholar] [CrossRef] [PubMed]
- Mariampillai, K.; Granger, B.; Amelin, D.; Guiguet, M.; Hachulla, E.; Maurier, F.; Meyer, A.; Tohme, A.; Charuel, J.L.; Musset, L.; et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurol. 2018, 75, 1528–1537. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tomasova Studynkova, J.; Charvat, F.; Jarosova, K.; Vencovsky, J. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology 2007, 46, 1174–1179. [Google Scholar] [CrossRef] [Green Version]
- Palmucci, S.; Di Mari, A.; Cancemi, G.; Pennisi, I.; Mauro, L.A.; Sambataro, G.; Sambataro, D.; Galioto, F.; Fazio, G.; Ferlito, A.; et al. Clinical and Radiological Features of Interstitial Lung Diseases Associated with Polymyositis and Dermatomyositis. Medicina 2022, 58, 1757. [Google Scholar] [CrossRef]
- Dalakas, M.C. Inflammatory muscle diseases. N. Engl. J. Med. 2015, 372, 1734–1747. [Google Scholar] [CrossRef] [Green Version]
- Hoogendijk, J.E.; Amato, A.A.; Lecky, B.R.; Choy, E.H.; Lundberg, I.E.; Rose, M.R.; Vencovsky, J.; de Visser, M.; Hughes, R.A. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. 2004, 14, 337–345. [Google Scholar] [CrossRef]
- Kundrick, A.; Kirby, J.; Ba, D.; Leslie, D.; Olsen, N.; Foulke, G. Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis. Semin. Arthritis Rheum. 2019, 49, 140–144. [Google Scholar] [CrossRef]
- Bentick, G.; Fairley, J.; Nadesapillai, S.; Wicks, I.; Day, J. Defining the clinical utility of PET or PET-CT in idiopathic inflammatory myopathies: A systematic literature review. Semin. Arthritis Rheum. 2022, 57, 152107. [Google Scholar] [CrossRef]
- Owada, T.; Maezawa, R.; Kurasawa, K.; Okada, H.; Arai, S.; Fukuda, T. Detection of inflammatory lesions by f-18 fluorodeoxyglucose positron emission tomography in patients with polymyositis and dermatomyositis. J. Rheumatol. 2012, 39, 1659–1665. [Google Scholar] [CrossRef]
- Tateyama, M.; Fujihara, K.; Misu, T.; Arai, A.; Kaneta, T.; Aoki, M. Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: Imaging of skeletal muscle inflammation. BMJ Open 2015, 5, e006763. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Motegi, S.I.; Fujiwara, C.; Sekiguchi, A.; Hara, K.; Yamaguchi, K.; Maeno, T.; Higuchi, T.; Hirasawa, H.; Kodaira, S.; Tomonaga, H.; et al. Clinical value of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. J. Dermatol. 2019, 46, 213–218. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Zhou, Y.; Wang, Q. Multiple values of (18)F-FDG PET/CT in idiopathic inflammatory myopathy. Clin. Rheumatol. 2017, 36, 2297–2305. [Google Scholar] [CrossRef] [PubMed]
- Arai-Okuda, H.; Norikane, T.; Yamamoto, Y.; Mitamura, K.; Fujimoto, K.; Takami, Y.; Wakiya, R.; Nakashima, S.; Dobashi, H.; Nishiyama, Y. (18)F-FDG PET/CT in patients with polymyositis/dermatomyositis: Correlation with serum muscle enzymes. Eur. J. Hybrid Imaging 2020, 4, 14. [Google Scholar] [CrossRef]
- Sun, L.; Dong, Y.; Zhang, N.; Lv, X.; Chen, Q.; Wei, W. [(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosing polymyositis/dermatomyositis. Exp. Ther. Med. 2018, 15, 5023–5028. [Google Scholar] [CrossRef] [Green Version]
- Matuszak, J.; Blondet, C.; Geny, B.; Namer, I.J.; Meyer, A. Comment on: Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity: Reply. Rheumatology 2019, 58, 2345–2346. [Google Scholar] [CrossRef]
- Pipitone, N.; Versari, A.; Zuccoli, G.; Levrini, G.; Macchioni, P.; Bajocchi, G.; Salvarani, C. 18F-Fluorodeoxyglucose positron emission tomography for the assessment of myositis: A case series. Clin. Exp. Rheumatol. 2012, 30, 570–573. [Google Scholar]
- Tanaka, S.; Ikeda, K.; Uchiyama, K.; Iwamoto, T.; Sanayama, Y.; Okubo, A.; Nakagomi, D.; Takahashi, K.; Yokota, M.; Suto, A.; et al. [18F]FDG uptake in proximal muscles assessed by PET/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis/dermatomyositis. Rheumatology 2013, 52, 1271–1278. [Google Scholar] [CrossRef] [Green Version]
- Martis, N.; Viau, P.; Zenone, T.; Andry, F.; Grados, A.; Ebbo, M.; Castela, E.; Brihaye, B.; Denis, E.; Liguori, S.; et al. Clinical value of a [18F]-FDG PET-CT muscle-to-muscle SUV ratio for the diagnosis of active dermatomyositis. Eur. Radiol. 2019, 29, 6708–6716. [Google Scholar] [CrossRef]
- Li, X.; Tan, H. Value of (18)F-FDG PET/CT in the detection of occult malignancy in patients with dermatomyositis. Heliyon 2020, 6, e03707. [Google Scholar] [CrossRef]
- Liang, J.; Cao, H.; Liu, Y.; Ye, B.; Sun, Y.; Ke, Y.; He, Y.; Xu, B.; Lin, J. The lungs were on fire: A pilot study of (18)F-FDG PET/CT in idiopathic-inflammatory-myopathy-related interstitial lung disease. Arthritis Res. Ther. 2021, 23, 198. [Google Scholar] [CrossRef]
- Cao, H.; Liang, J.; Xu, D.; Liu, Y.; Yao, Y.; Sun, Y.; He, Y.; Lin, J. Radiological Characteristics of Patients With Anti-MDA5-Antibody-Positive Dermatomyositis in (18)F-FDG PET/CT: A Pilot Study. Front. Med. 2021, 8, 779272. [Google Scholar] [CrossRef]
- Walter, M.A.; Melzer, R.A.; Schindler, C.; Muller-Brand, J.; Tyndall, A.; Nitzsche, E.U. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 674–681. [Google Scholar] [CrossRef] [PubMed]
- Selva-O’Callaghan, A.; Grau, J.M.; Gamez-Cenzano, C.; Vidaller-Palacin, A.; Martinez-Gomez, X.; Trallero-Araguas, E.; Andia-Navarro, E.; Vilardell-Tarres, M. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am. J. Med. 2010, 123, 558–562. [Google Scholar] [CrossRef] [PubMed]
- Trallero-Araguas, E.; Gil-Vila, A.; Martinez-Gomez, X.; Pinal-Fernandez, I.; Alvarado-Cardenas, M.; Simo-Perdigo, M.; Selva-O’Callaghan, A. Cancer screening in idiopathic inflammatory myopathies: Ten years experience from a single center. Semin. Arthritis Rheum. 2022, 53, 151940. [Google Scholar] [CrossRef]
- Girija, M.S.; Tiwari, R.; Vengalil, S.; Nashi, S.; Preethish-Kumar, V.; Polavarapu, K.; Kulanthaivelu, K.; Arbind, A.; Bardhan, M.; Huddar, A.; et al. PET-MRI in idiopathic inflammatory myositis: A comparative study of clinical and immunological markers with imaging findings. Neurol. Res. Pract. 2022, 4, 49. [Google Scholar] [CrossRef]
- Maliha, P.G.; Hudson, M.; Abikhzer, G.; Singerman, J.; Probst, S. 18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications. Nucl. Med. Commun. 2019, 40, 377–382. [Google Scholar] [CrossRef]
- Wu, W.; Guo, L.; Fu, Y.; Wang, K.; Zhang, D.; Xu, W.; Chen, Z.; Ye, S. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. Clin. Rev. Allergy Immunol. 2021, 60, 293–304. [Google Scholar] [CrossRef] [PubMed]
- Gono, T.; Masui, K.; Nishina, N.; Kawaguchi, Y.; Kawakami, A.; Ikeda, K.; Kirino, Y.; Sugiyama, Y.; Tanino, Y.; Nunokawa, T.; et al. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2021, 73, 677–686. [Google Scholar] [CrossRef]
- Li, S.; Sun, Y.; Shao, C.; Huang, H.; Wang, Q.; Xu, K.; Zhang, X.; Liu, P.; Zeng, X.; Xu, Z. Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: A retrospective study of 679 adult cases. Rheumatology 2021, 60, 1195–1204. [Google Scholar] [CrossRef]
- Barba, T.; Fort, R.; Cottin, V.; Provencher, S.; Durieu, I.; Jardel, S.; Hot, A.; Reynaud, Q.; Lega, J.C. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. Autoimmun. Rev. 2019, 18, 113–122. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Chen, Z.; Long, Y.; Zhang, B.; He, Q.; Tang, K.; Zhang, X. 18F-FDG PET/CT and HRCT: A combined tool for risk stratification in idiopathic inflammatory myopathy-associated interstitial lung disease. Clin. Rheumatol. 2022, 41, 3095–3105. [Google Scholar] [CrossRef] [PubMed]
Total number of patients | 29 |
Mean age at diagnosis (years) | 48.7 |
Sex (female) | 19 (65.5%) |
Myositis subset | |
Dermatomyositis | 22 (75.8%) |
Polymyositis | 7 (24.1%) |
Overlap syndrome | 0 (0.0%) |
Symptoms | |
Muscle weakness | 24 (82.7%) |
Skin lesions | 22 (75.8%) |
Cough | 5 (17.2%) |
Dyspnea | 5 (17.2%) |
Dysphagia | 9 (31%) |
Arthralgia | 5 (17.2%) |
Positive ANA | 21 (72.4%) |
ANA, titer | |
1/80 | 8 (27.5%) |
1/160 | 4 (13.7%) |
1/320 | 4 (13.7%) |
1/640 | 2 (0.6%) |
1/1280 | 3 (10.3%) |
Myositis-specific autoantibodies (17/29) | |
SAE | 2 (0.6%) |
SRP | 0 |
MDA5 | 1 (0.3%) |
MI-2 | 1 (0.3%) |
Ro52 | 0 |
NXP2 | 2 (0.6%) |
TIF1-γ | 4 (13.7%) |
PI12 | 1 (0.3%) |
PI7 | 3 (10.3%) |
JO-1 | 3 (10.3%) |
CK level (U/L) at diagnosis (mean) [range] | 3125.14 [27–18,760] |
CRP level (mg/L) at diagnosis (mean) | 30.3 |
Positive electromyography | 17/27 (62.9%) |
Positive whole-body muscle MRI | 10/19 (52.6%) |
Muscle activity on [18F]FDG-PET/CT | 13/27 (48.1%) |
Positive skin biopsy | 11/17 (64.7%) |
Positive muscle biopsy | 11/15 (73.3%) |
Interstitial lung diseases | 8 (27.5%) |
Cancer detected by [18F]FDG-PET/CT | 3/27 (11.1%) |
Treatment | |
Corticosteroids | 27 (93%) |
Methotrexate | 18 (62%) |
Azathioprine | 9 (31%) |
Mycophenolate mofetil | 1 (0.3%) |
Rituximab | 2 (0.6%) |
IVIG | 5 (17.2%) |
Opportunistic infection | 3 (10.3%) |
Death | 4 (13.7%) |
PET/CT-Positive | PET/CT-Negative | p Value | |
---|---|---|---|
EMG (+) | 12 | 4 | 0.0036 |
EMG (−) | 1 | 9 | |
MRI (+) | 8 | 3 | 0.0198 |
MRI (−) | 1 | 7 |
PET/CT-Positive | PET/CT-Negative | p Value | |
---|---|---|---|
Dyspnea (+) | 4 | 0 | 0.002 |
Dyspnea (−) | 3 | 20 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yildiz, H.; Lepere, C.; Zorzi, G.; Gheysens, O.; Roodhans, F.; Pothen, L. [18F]FDG-PET/CT in Idiopathic Inflammatory Myopathies: Retrospective Data from a Belgian Cohort. Diagnostics 2023, 13, 2316. https://doi.org/10.3390/diagnostics13142316
Yildiz H, Lepere C, Zorzi G, Gheysens O, Roodhans F, Pothen L. [18F]FDG-PET/CT in Idiopathic Inflammatory Myopathies: Retrospective Data from a Belgian Cohort. Diagnostics. 2023; 13(14):2316. https://doi.org/10.3390/diagnostics13142316
Chicago/Turabian StyleYildiz, Halil, Charlotte Lepere, Giulia Zorzi, Olivier Gheysens, Fabien Roodhans, and Lucie Pothen. 2023. "[18F]FDG-PET/CT in Idiopathic Inflammatory Myopathies: Retrospective Data from a Belgian Cohort" Diagnostics 13, no. 14: 2316. https://doi.org/10.3390/diagnostics13142316